Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseNHL, CNS-NHLSubgroupICD10C83.3MeSHCentral Nervous System NeoplasmsLymphoma, Non-HodgkinSequenceFreiburg CNS-NHL StudyMATRIXChemotherapyChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaNo. Substances23 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFluconazoleFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFluconazoleFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFluconazoleFosaprepitantGranisetronParacetamolPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFluconazoleFosaprepitantGranisetronParacetamolPrednisoloneNo. Substances69Protocol classificationTherapy classificationcurrent standardstudy analogIntensityhigh doseTherapy indicationFirst lineTherapy phaseautologous stem cell transplantationconditioningTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaIncrease AminotransferasesInfectionsLeukopeniaMucositisNeutropeniaPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorIllerhaus GDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreprimäres ZNS-NHL, ErstdiagnoseOriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollMATRix / IELSG43 StudieProtocols in Revision 2 protocols foundProtocols under revision.Carmustine 400 / Thiotepa 5, consolidation before autologous Stem Cell Transplantation, CNS- Non-Hodgkin Lymphoma (PID890 V2.1)Rituximab 375 / Carmustine 400 / Thiotepa 5, CNS- Non-Hodgkin Lymphoma, conditioning, cycle 5 (PID1883 V1.0)
